

**Experience in the use of the drug "Donovit"  
in general clinical practice  
(Medic clinic)**

Over the past 10 years, a lot of medicines have appeared on the “market” of medical preparations that have immune corrective, including “antitumor” activity. Most of them, due to low efficacy in population studies, the presence of side effects and high cost, have not stood the test of time. However, a number of drugs, especially of a plant nature, remain in the arsenal of doctors as accompanying drugs and having a polyvalent effect.

One of these drugs is Donovit-VS (hereinafter referred to as Donovit).

We use "Donovit" as part of the complex therapy of immunodeficiency states, persistent viral infections, neoplastic diseases of the III-IV clinical stage and basic monotherapy and maintenance - after PCT, radiation therapy of tumors of various origins.

From 2003 to 2005 we have treated 355 patients.

**I. Of these, by nosological forms and classes**

№	Class and disease code	Name of the disease by class	Years			Total
			2003	2004	2005	
1.	<b>I.</b>	<b>Infectious diseases</b>	<b>14</b>	<b>40</b>	<b>44</b>	<b>98</b>
	BOO 02 B-25 B-27	Persistent herpes infections (HSV1-2, CMV, EBV)	4	26	32	62
	B 09	Acute respiratory diseases	10	14	12	36
2.	<b>II.</b>	<b>Neoplasms</b>	<b>6</b>	<b>23</b>	<b>14</b>	<b>43</b>
	C 16	Tumors of the stomach	2	6	5	
	C18-20	Colon tumors				
	C 26	Tumors of the gastrointestinal tract of unspecified localization	1	2	2	
	C 34	Tumors of the lungs and bronchi	1	6	3	
	C51	Tumors of the uterus	2	1	-	
	C61-63	Tumors of the prostate and testicles	-	2	1	
	C64-67 C 71 C75	Tumors of the kidney and bladder Brain tumors Thyroid tumors	-	2 2 1	1 1 -	

3.	<b>V.</b>	<b>Mental and behavioral illnesses</b>	<b>6</b>	<b>12</b>	<b>21</b>	<b>39</b>
	F40-48	Phobic and somatoform disorders	6	12	21	
4.	<b>X.</b>	<b>Diseases of the respiratory system</b>	<b>8</b>	<b>13</b>	<b>27</b>	<b>48</b>
	J44	Chronic obstructive pulmonary disease	2	4	6	
	J45	Bronchial asthma	6	9	21	
5.	<b>XL</b>	<b>Digestive system diseases</b>	<b>1</b>	<b>6</b>	<b>12</b>	<b>19</b>
	K 73-74	Chronic hepatitis and liver cirrhosis	1	6	12	
6.	<b>XII.</b>	<b>Skin and subcutaneous tissue diseases</b>	<b>21</b>	<b>31</b>	<b>20</b>	<b>72</b>
	L02	Furunculosis	1	3	-	
	L20	Atopic dermatitis	6	8	11	
	L40	Psoriasis	2	3	1	
	L50	Urticaria	12	17	8	
7.	<b>XIII.</b>	<b>Diseases of the musculoskeletal system</b>	<b>-</b>	<b>16</b>	<b>38</b>	<b>54</b>
	<b>M15</b>	Arthrosis	-	6	18	
	<b>M42</b>	Osteochondrosis	-	2	1	
<b>TOTAL:</b>						<b>373</b>

All patients who applied (inpatient or outpatient) underwent the full range of necessary examinations before treatment, intermediate control and after treatment. In addition to "routine" studies, serological studies were carried out for Ig M, G, PCR HSV, CMV, EBV, HZV; HBV, HCV; antimicrosomal, antimitochondrial, antinuclear antibodies; AFP, PSA, CEA; control ultrasound, X-ray, CT examination of the chest and abdominal cavity.

Terms of treatment from 2 weeks for acute diseases (acute respiratory infections, acute allergic reactions) to 2 years (chronic hepatitis, persistent viral infections, tumors, etc.).

## II. Treatment outcome by disease class.

<b>Class</b>	<b>Nosological form</b>	<b>Recovery (remissions &gt; 2 years)</b>	<b>Improvement in remission up to 1 year</b>	<b>Without dynamics</b>	<b>Total</b>
<b>BOO 02</b>	Persistent HSV 1-2 infections	<b>14</b>	<b>10</b>	<b>6</b>	<b>30</b>
<b>B 25</b>	CMV infection	<b>6</b>	<b>12</b>	<b>2</b>	<b>20</b>
<b>B 27</b>	EBV infection	<b>2</b>	<b>7</b>	<b>3</b>	<b>12</b>

Of the total number of patients treated for persistent herpes infections, recovery (remission > 2 years) - 73% of patients, without effect - 15%.

In patients with tumors:

Class II	Neoplasms	Convalescence	Improvement	Without speakers	Total
C16-75		-	31	12	43

In the treatment of oncological diseases, III-IV clinical stages of diseases took place, of which 86% were after surgical treatment, chemotherapy and radiation therapy. "Donovit" was included in the schemes as a therapy to "accompany" the main treatment; the consequences of toxic and radiation reactions, and maintenance (symptomatic) therapy of late complications of tumor processes. Terms of treatment from 2 months to 2.5 years. Improvement was determined by general well-being, stabilization of hemodynamics, reduction in the manifestations of compression, edematous and dyspeptic syndromes. The timing of the onset of primary effects from 2 weeks to 1 month. The courses of treatment were continuous with periodic consolidation of the effect (return to the "hill" scheme after 2-3 months of maintenance therapy). A particularly pronounced effect with prolongation of survival was observed in patients with brain and lung tumors. So out of the total number of positive reactions to treatment - 70%, and in patients with tumors of these localizations - 82%.

The use of "Donovit" in COPD, bronchial asthma, osteochondrosis, depressive syndromes enhanced the effect of basic drugs, reduced their dose, and made it possible to achieve a clinical effect in a shorter time.

Side effects when using the drug "Donovit" were not observed in any case. Withdrawal from treatment was not accompanied by a withdrawal syndrome. Allergic reactions were not noted.

Thus, the phytopreparation "Donovit-VS" can be successfully used in mono or complex therapy of a number of diseases.

Honored Doctor of Ukraine

(signature)

V.I. Nazarenko

(seal)

